Healthcare · Biotech & Pharma
Altos Labs
San Francisco, USA · Series C
Implied valuation
Probability modeled from funding stage, momentum & liquidity signals.
Valuation Trajectory
Funding-round staircase from founding · log scale. Modeled round ladder anchored to the current valuation — illustrative, not a published figure.
IPO Model Drivers
Why the odds read this way
Factor weights are illustrative decompositions of the modeled IPO probability, not guarantees.
Down-Round Risk
Valuation downside pressure
Mixed signals — limited valuation history with 33% modeled IPO odds keep down-round risk in the middle band.
Asset brief
Altos Labs is a Healthcare · Biotech & Pharma company last marked at $6.33B. Stage: Series C, $1.5B raised to date. No verified market-moving events in the last 30 days.
Altos Labs is a biotechnology research company aiming to develop life extension therapies that can halt or reverse the human aging process. The company focuses on cellular rejuvenation programming to restore cell health and resilience, with the goal of reversing disease to transform medicine.
Capital Timeline
Funding & liquidity milestones
Series C
$1.5B raised · $6.33B